"Heart" Technology Breakthrough: The Second Affiliated Hospital of Wenzhou Medical University Successfully Performs Wenzhou's First RhythPulse® PFA Procedure Using Xuanyu Medical's System
ShineyoMedical
Provider of Atrial Fibrillation Electrophysiology and Peripheral Vascular Intervention Solutions
Click the blue words to follow us
ENTERPRISE
September 17, Department of Cardiology, Second Affiliated Hospital of Wenzhou Medical UniversityProfessor Li Yuechun's Team, coordinating with anesthesiologists and the medical team, successfully applied RhythPulse®Pulse Field Ablation Catheter Performs Atrial Fibrillation Pulse Field Ablation Surgery for a Patient with Atrial Fibrillation. This surgery is one of the first batch of RhythPulse in China.®Clinical Application of Pulsed Ablation, Also the First Case of RhythPulse in Wenzhou Region®Application of Pulsed Electric Field Ablation Catheters.
Atrial Fibrillation Ablation
Traditional surgical methods for atrial fibrillation patients mainly include radiofrequency ablation and cryoablation, both of which destroy lesions through temperature and may also damage surrounding tissues. In contrast, the latest pulsed field ablation for atrial fibrillation acts like a "precision-guided missile," targeting only abnormal electrical signals without harming other tissues. It features precision, efficiency, and safety.
Surgical Procedure
The patient is a 70-year-old male with paroxysmal atrial fibrillation. Preoperative detailed evaluation of the pulmonary vein anatomy and ostial diameter was conducted using left atrial CTA imaging. The diameter of the upper pulmonary vein ostium was approximately 13mm, and the lower pulmonary vein ostium was approximately 9mm. Therefore, ShineyoMedical's RhythPulse was selected for use.®The 15mm model of the pulsed ablation catheter system was used for ablation at the pulmonary vein site.
The patient's surgery was performed under general anesthesia. The femoral vein was punctured and the surgical access was established, with a decapolar catheter placed in the coronary sinus. Atrial septal puncture was completed under DSA guidance, successfully establishing access to the left atrium. RhythPulse was then introduced.®The PFA catheter was delivered to the left atrium for left atrial modeling and pulmonary vein potential mapping. Then, the catheter was placed at the ostium and vestibule regions of each pulmonary vein for ablation. The pulmonary vein potentials rapidly disappeared, achieving complete isolation, and successfully completing PVI+. The entire ablation process took only 30 minutes, the surgery proceeded smoothly with no intraoperative complications, and the patient's vital signs were stable postoperatively.
Ostium and vestibule validation of the right upper pulmonary vein (intraoperative confirmation of atrial fibrillation originating from the right upper pulmonary vein)
Verification of the Right Lower Pulmonary Vein Ostium
Verification of the Left Upper Pulmonary Vein Ostium
Verification of the Left Lower Pulmonary Vein Ostium
Wenzhou Medical University Second Affiliated Hospital, as a regional medical center, has a wide coverage. This time, the successful application of RhythPulse, produced by ShineyoMedical.®The system can provide higher-quality medical services to more patients.
Expert Profile
Li Yuechun
The Second Affiliated Hospital of Wenzhou Medical University
M.D., Ph.D., Professor, Chief Physician, Doctoral Supervisor
Training Mentor for Arrhythmia Interventions at the National Health Commission (NHC) of China, Global Teaching Expert for Left Atrial Appendage Occlusion; Member of the Youth Electrophysiology Working Committee of the Heart Rhythm Society and Pacing Branch of the Chinese Medical Association; Member of the Left Atrial Appendage Occlusion Working Committee of the Heart Rhythm Society and Pacing Branch of the Chinese Medical Association; Member of the Heart Rhythm and Electrocardiogram Branch of the China International Medical Exchange Association; Member of the Arrhythmia Professional Committee of the National Pharmaceutical Technology Market Association; Standing Member of the Left Atrial Appendage Occlusion Working Group of the China Atrial Fibrillation Center Alliance; Member of the Youth Committee of the Chinese Heart Rhythm Society; Deputy Leader of the Cardiogenic Stroke Study Group of the Zhejiang Cardiovascular Disease Society; One of the first Leading Talents in Zhejiang Province’s Universities, Leading Academic Figure among Middle-aged and Young Professionals in Zhejiang Province's Universities; Second-tier Talent under the "151 Talent Project" of Zhejiang Province, Innovative Talent in Healthcare of Zhejiang Province, and one of the first group of Rising Stars in Medicine in Zhejiang Province; Renowned Doctor of Wenzhou, Top Ten Outstanding Youths of Wenzhou; Review Expert for High-level Medical Talents at the NHC of China, Review Expert for the National Natural Science Foundation of China.
Published more than 50 SCI papers as the first author or corresponding author, including top journals in the field such as "JAMA Internal Medicine," "Circulation: Arrhythmia and Electrophysiology," "JACC: Clinical Electrophysiology," and "Heart Rhythm."
Completed the first "one-stop" surgery in China for atrial fibrillation radiofrequency ablation combined with left atrial appendage thrombus occlusion. Completed the first implantation of a bioresorbable left atrial appendage occluder in East China. Completed the first left atrial appendage thrombus occlusion under a cerebral protection device in Zhejiang Province. Original proposed Persistent Atrial Fibrillation PROMISED ablation technique (Left Atrial Anterior Wall BOX ablation technique). For four consecutive years, ranked among the top two in Zhejiang Province for the volume of "one-stop" surgeries combining atrial fibrillation radiofrequency ablation with left atrial appendage occlusion and for left atrial appendage occlusion surgeries.
END
【ShineyoMedical RhythPulse®-PFA System】
ShineyoMedical's RhythPulse®-PFA System is the first approved Pulse Field Ablation (PFA) system in China that integrates multi-channel, large focal, and targeted ablation, primarily used for treating drug-refractory and recurrent atrial fibrillation and other types of rapid arrhythmias. Its core advantages include:
Large Focal Design:Using the world's first 10mm ring ablation catheter, a single discharge can cover a lesion area with a diameter of 10mm, improving the ablation efficiency by more than three times compared to traditional technology.
Targeted Ablation Technology:Equipped with an intelligent contact detection module, it monitors the contact status between the electrode and myocardial tissue in real time, reducing the risk of hemolysis caused by ineffective discharge. Postoperative plasma free hemoglobin content decreased by 50%.
Excellent clinical validation:In a clinical trial involving 151 cases, the immediate success rate was 100%, and the success rate for atrial fibrillation treatment at 12 months post-operation reached 85.07%, meeting internationally leading standards.
